Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

Study participants will be 40 men and women between the ages of 18 and 75 who provide appropriate consent and who are agreeable to study requirements
Diagnosed with mild to moderate traumatic brain injury as defined by an initial Mayo Traumatic Brain Injury Severity Scale
Have memory impairments defined by a Hopkins Verbal Learning Test delayed recall score which falls less than or equal to 1.5 standard deviation below the mean.

Exclusion Criteria:

Refusal to give informed consent
A previous Central Nervous System illness or injury, including seizure that exhibits residual symptoms.
Current post-traumatic seizure disorder
A previous diagnosis of a psychotic disorder
Current or previous (in the last 6 months) treatment history for alcohol or substance dependency
Medications affecting noradrenergic or dopaminergic systems, alpha-adrenergic antihypertensives, antidepressant, phenobarbital, Monoamine oxidase inhibitor (MAOI), scheduled benzodiazepines, psychoactive herbal supplements (including Kava, St. John's wort), or nutritional supplements or within at least 14 days of discontinuing treatment with the above medications or supplements.
A known suicide risk
A pregnant or breastfeeding woman
Uncontrolled narrow-angle glaucoma
Serious and/or unstable medical comorbidity (e.g., AIDS, cancer, history of uncontrolled hypertension or cardiovascular disease) psychological condition, or clinically significant laboratory abnormality that in the opinion of the investigator would compromise participation in the study or be likely to lead to hospitalization during the course of the study
Liver enzymes > 1.5 times upper limit of normal
Patients with end-stage renal disease (requiring dialysis) or severe renal impairment
Known hypersensitivity to duloxetine or any of the inactive ingredients